SSgA Active Trust - Health Care Select Sector SPDR
XLV
Get informed when a big investor buys or sells
+ FollowShare Statistics
| Market cap | $771.22 Billion |
|---|---|
| Enterprise Value | $771.21 Billion |
| Dividend Yield | $2.51 (1.68%) |
| Earnings per Share | $- |
| Beta | 0.56 |
| Outstanding Shares | - |
Return
| Return on Equity | 41.44% |
|---|---|
| Return on Assets | 32.58% |
| Return on Invested Capital | 29.21% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 14617.09 |
| Enterprise Value to EBIT | 60107.16 |
| Enterprise Value to Net Income | 47597 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.5397▲ 51.43% |
|---|---|
| Total Calls | 8,765,443▼ 39.31% |
| Total Puts | 13,495,976▼ 8.87% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 72.12%▼ 0.38% |
|---|---|
| Total Invested | $27.66B▼ 6.95% |
| Investors Holding | 1,861▼ 44.00% |
ESG Score
No data
About State Street My2026 Municipal Bond ETF
The State Street My2026 Municipal Bond ETF is an actively managed target maturity strategy that provides exposure primarily to municipal bonds maturing in 2026 and is designed to distribute any remaining principal and liquidate on or abo...
Relevant Senate Committees
This is one of the most powerful committees for the healthcare sector, controlling taxation, trade, and entitlement spending. It directly impacts corporate valuations through tax policy and profoundly influences the healthcare and pharmaceutical sectors through its control over Medicare and Medicaid funding and reimbursement rates.
This committee directly allocates discretionary federal spending. Its subcommittees determine precise funding for NIH research, Medicare/Medicaid programs, and VA healthcare, directly impacting the revenue streams and research opportunities for a vast array of healthcare companies.
This is a primary regulatory body for the healthcare sector. It oversees the FDA (drug and device approval), NIH (research funding), and labor laws, directly impacting the operational environment, research, and workforce costs for pharmaceutical, biotech, and healthcare service companies.
This committee oversees antitrust laws and intellectual property. Antitrust enforcement directly impacts mergers and acquisitions in the healthcare sector, while intellectual property protection (patents) is absolutely critical for the pharmaceutical and biotechnology industries.